2026
Nordyke RJ, Cyr P , Jensen I . Gene therapy development programs are both growing and evolving in the face of commercial headwinds. Poster Session 3/No. HPR71 , ISPOR 2026, Philadelphia, PA, May 19, 2026.
View Abstract
Publication: Abstracts and Presentations
Nordyke RJ, Jensen I , Hooda N , Miller B . Rising levels of innovation in expedited designations among FDA-approved drugs: 2012-2024. Poster Session 2/No. HPR63 , ISPOR 2026, Philadelphia, PA, May 18, 2026.
View Abstract
Publication: Abstracts and Presentations
2025
Preib MT, Emden MR, Sacks NC , Mitrani-Gold FS, Ju S, Kawano Y, Kawamatsu S, Joshi AV. 2025. Prevalence and economic evaluation of acute uncomplicated cystitis in women from Japan: A retrospective cohort study. JAC Antimicrob Resist 7(5):dlaf178; doi: 10.1093/jacamr/dlaf178 . PMID: 41113066.
View Abstract
Publication: Manuscripts
Desai NR, Fermann G, Pollack C, Venkatesh A, Hooda N , Jiang X , Sacks N , Holtz A, et al. Emergency department visits for PSVT: An analysis of the HCUP Nationwide Emergency Department Sample. Abstract 391, American College of Emergency Physicians (ACEP) Research Forum. Ann Emerg Med 86(3S1):S169; doi: 10.1016/j.annemergmed.2025.06.409 . Salt Lake City, UT, September 2025.
View Abstract
Publication: Abstracts and Presentations
Sidhu MK, Miller B , Jensen I , Rabiner P. 2025. Abstract EE171: Conceptual framework for a de novo cost-effectiveness model in glycogen storage disease type Ia (GSDIa). Value in Health 28(6-Sup1):S93-S94; doi: 10.1016/j.jval.2025.04.463 .
View Abstract
Publication: Abstracts and Presentations
Duong T, Haselkorn T, Miller B , Coats J, Jensen I , Ward E, Wood M, Graham RJ, Servais L. 2025. A real-world analysis of the impact of X-linked myotubular myopathy on caregivers in the United States. Orphanet J Rare Dis 20(1):224. doi: 10.1186/s13023-025-03583-w . PMID: 40355957.
View Abstract
Publication: Manuscripts
Desai NR, Piccini JP, Sacks NC , Reichert H , Hooda N , Jiang X , Blood AJ, Holz A, et al. Emergency department visits and inpatient admissions for atrial fibrillation in the United States (US): 2015-2019. Abstract I10, Academy of Managed Care Pharmacy ( AMCP) Annual Meeting. J Manag Care Spec Pharm 31(3-a Suppl):S74; doi: 10.18553/jmcp.2025.31.3-a.s1. Houston, TX, March 31-April 3, 2025.
View Abstract
Publication: Abstracts and Presentations
Tao C, Nicholson G, Desai N, Sacks N , Sherwood R, Pokorney S. Budget impact of etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States. Abstract I9, AMCP Annual Meeting. J Manag Care Spec Pharm 31(3-a Suppl):S73; doi: 10.18553/jmcp.2025.31.3-a.s1 . Houston, TX, March 21-April 3, 2025.
View Abstract
Publication: Abstracts and Presentations
2024
Haselkorn T, Hughes W, Schara-Schmidt U, Lennox A, Roca A, Miller B , Jensen I , Solomon F, et al. 2024. Abstract PCR257: Real-world impact of x-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Value in Health 27(12-Sup):S557; doi: 10.1016/j.val.2024.10.3499 .
View Abstract
Publication: Abstracts and Presentations
Olaye A, Bean K, Velikanova R, Wolters S, Miller B , Jensen I , Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693, ISPOR Europe 2024. Value in Health 27(12 Sup):S191; doi: 10.1016/j.jval.2024.10.973 . Barcelona, November 2024.
View Abstract
A Division of